Smith Sarah S, Hilas Olga
J Pediatr Pharmacol Ther. 2021;26(7):669-674. doi: 10.5863/1551-6776-26.7.669. Epub 2021 Sep 24.
Peanut () Allergen Powder-dnfp (Palforzia, Aimmune™ Therapeutics, Inc.; Brisbane, CA) is the first FDA-approved oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, in patients with peanut allergy. It may be initiated in individuals 4 to 17 years of age and continued for maintenance in those 4 years of age and older. Initiation and dose titration require a stepwise approach and the supervision of a health care professional. Patients taking Peanut () Allergen Powder-dnfp should also follow a peanut-avoidant diet. In addition, patients should have an injectable epinephrine product in case of drug-related anaphylaxis. Commonly reported adverse reactions include gastrointestinal, respiratory, and dermatologic manifestations that are frequently associated with allergic reactions.
花生（）变应原粉末-dnfp（Palforzia，Aimmune™治疗公司；加利福尼亚州布里斯班）是首个获美国食品药品监督管理局批准的口服免疫疗法，适用于减轻花生过敏患者的过敏反应，包括过敏反应。该疗法可用于4至17岁的个体，并在4岁及以上的人群中持续维持治疗。开始治疗和剂量滴定需要采用逐步方法并在医疗保健专业人员的监督下进行。服用花生（）变应原粉末-dnfp的患者还应遵循避免食用花生的饮食。此外，患者应备有可注射肾上腺素产品以防药物相关的过敏反应。常见的不良反应包括经常与过敏反应相关的胃肠道、呼吸道和皮肤表现。
